ANOTHER DANGER in FLU VACCINES: NANOPARTICLES

[Guest guest]

This Global Research story is confirmed below by Reuters and other sources, including patent application data etc.

 

http://www.globalresearch.ca/index.php?context=va & aid=15092

 

 

Nano Particles used in Untested H1N1 Swine Flu Vaccines

Part III: `It's the vaccines, Stupid!

by F. William Engdahl

 

..

 

 

 

Global Research, September 13, 2009

 

 

 

 

 

 

Email this article to a friend

Print this article

 

 

 

 

 

 

 

 

 

 

 

 

Vaccines

which have been approved by the responsible government authorities for

vaccination against the alleged H1N1 Influenza A Swine Flu have been

found to contain nano particles. Vaccine makers have been experimenting

with nanoparticles as a way to "turbo charge" vaccines for several

years. Now it has come out that the vaccines approved for use in

Germany and other European countries contain nanoparticles in a form

that reportedly attacks healthy cells and can be deadly.

In 2007 researchers at the Ecole Polytechnique Fédérale de Lausanne (EPFL) announced in an article in the journal, Nature Biotechnology, that they had developed a

"nanoparticle that can deliver vaccines more effectively, with fewer

side effects, and at a fraction of the cost of current vaccine

technologies." The article went on to describe the effects of their

breakthrough: "At a mere 25 nanometers, these particles are so tiny

that once injected, they flow through the skin's extracellular matrix,

making a beeline to the lymph nodes. Within minutes, they've reached a

concentration of DCs thousands of times greater than in the skin. The

immune response can then be extremely strong and effective." 1

There

is only one small problem with vaccines containing nanoparticles—they

can be deadly and at the least cause severe irreparable health damage.

Nanoparticles,

promoted in the mass media as the new wonder revolution of science, are

particles that have been produced vastly smaller than deadly asbestos

particles which caused severe lung damage and death before being

outlawed. Particles at a nano size, (nm = 0,000000001 Meter) fuse

together with the membranes of our body cell membranes and, according

to recent studies in China and Japan, continuously destroy cells once

introduced into the body. Once they interact with the body's cellular

structure, they cannot be removed. Modern medicine euphemistically

terms the phenomenon, a continuing infectious reaction.

Since

the asbestos scandal, it has been established that particles in size a

millionth of a meter, because of their enormous attractive force,

penetrate all cells, destroying all those they come into contact with.

Nanoparticles are far smaller than asbestos fibers.

Beijing Tests confirm deadly effects on humans

The

fact that WHO, the European Medicines Evaluation Agency, the German

Robert Koch Institute and other health bodies today would permit the

population to be injected with largely untested novel vaccines

containing nanoparticles says more about the powerful pharma lobby in

Euiropean politics than it does about the sanity or moral integrity of

the civil servants responsible for health of the general public.

The September 2009 issue of the respected European Respiratory Journal, made public on 19 August, and available since 21 August online, contains a peer-reviewed article with the title, "Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma."

The

article describes tests carried out in 2008 at the elite Beijing

Chaoyang Hospital on seven young women. All seven, ages 18-47 had been

exposed to nanoparticles for 5–13 months in their common workplace. All

were admitted to the hospital with shortness of breath and pleural

effusions, or excessive fluids surrounding the lungs, inhibiting

breathing. None of the seven had ever smoked and none were in any

special risk group. Doctors carefully tested for every possibility and

confirmed that the lung problems had a common origin—regular inhalation

of nanoparticles in their factory. They had been exposed to Polyacrylat

nanoparticles.

The

tests confirmed the nanoparticles had set off a "super-meltdown"

reaction in the patients. Despite all heroic efforts of doctors, two of

the seven died from the lung complications. 2

In their report, the scientists concluded something so alarming it is necessary to quote at length:

 

"Immunological

tests, examinations of bacteriology, virology and tumour markers,

bronchoscopy, internal thoracoscopy and video-assisted thoracic surgery

were performed. Surveys of the workplace, clinical observations and

examinations of the patients were conducted. Polyacrylate, consisting

of nanoparticles, was confirmed in the workplace. Pathological

examinations of patients' lung tissue displayed nonspecific pulmonary

inflammation, pulmonary fibrosis and foreign-body granulomas of pleura.

Using transmission electron microscopy, nanoparticles were observed to

lodge in the cytoplasm and caryoplasm of pulmonary epithelial and

mesothelial cells, but are also located in the chest fluid. These cases

arouse concern that long-term exposure to some nanoparticles without

protective measures may be related to serious damage to human lungs."3

To

date Animal studies and in vitro experiments show that nanoparticles

can result in lung damage and other toxicity in animals, but no reports

on the clinical toxicity in humans due to nanoparticles prior to the

Beijing study had been made.

The

Beijing Chaoyang Hospital study has now conclusively confirmed that

nanoparticles cause lung damage and other toxicity in humans as well.

At this point in time, when two of the approved vaccines planned to be

mass distributed in Germany and elsewhere contain nanoparticles,

failure of the relevant responsible public health and epidemiology

officials to order an immediate emergency freeze on distribution of any

vaccine containing nanoparticles can only be considered tantamount to

criminal negligence. Hopefully the responsible authorities will react

in time to avert a possible human health catastrophe orders of

magnitude worse than the worst case of Swine Flu reported to date.

 

F. William Engdahl is author of Full Spectrum Dominance: Totalitarian Democracy in the New World Order. He may be reached via his website, www.engdahl.oilgeopolitics.net

 

 

Notes:

 

1 EPFL, Bioengineering researchers from the EPFL in Lausanne, Switzerland,

have developed and patented a nanoparticle that can deliver vaccines

more effectively, with fewer side effects, and at a fraction of the

cost of current vaccine technologies, accessed in www.azonano.com/nanotechnology%20news.asp?catid=13.

2 Song Y, Li X, Du X, Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma , European Respiratory Journal, 9/2009, 34(3): 559-567.

3 Ibid.

 

 

F. William Engdahl is a frequent contributor to Global Research. Global Research Articles by F. William Engdahl

 

 

 

 

http://www.reuters.com/article/marketsNews/idUSBNG41041620090817

Print | Close this windowUPDATE 2-BioSante says its adjuvant raises H1N1 vaccine efficacyMon Aug 172009 1:02pm EDT

 

* BioVant with new H1N1 vaccine gives 100 pct protection

 

* Plans to license BioVant to a vaccine maker

 

* Shares surge 28 pct (Adds company commentsupdates share movement)

 

By Anand Basu

 

BANGALOREAug

17 (Reuters) - BioSante Pharmaceuticals Inc (BPAX.O:

QuoteProfileResearchStock Buzz) said its adjuvantBioVantincreases the

efficacy of vaccines for multiple flu strainsincluding a potential new

vaccine against H1N1 virusor swine flusending its shares up 28 percent.

 

An adjuvant

is an ingredient that boosts the immune system responsewhich means that

less active ingredient is needed in each dose.

 

BioSante is

looking to license BioVant to a vaccine maker and expects to earn

royalties from the adjuvantsenior Director of Operations Bill Milling

said by phone.

 

"We have had some talks with some companiesbut nothing has gone as far as being at the serious level yet" Milling said.

 

The specialty

pharmaceutical company said BioVant when used with a potential new

vaccine against swine flu resulted in 100 percent protection from

symptoms of illnessincluding weight loss and death in animal studies.

 

Swine and bird flu vaccines using BioVant may allow for availability of a greater number of lower-dose vaccinesthe company said.

 

Shares of the

company touched a high of $2.50 before paring some gains to trade up 25

cents at $2.21 Monday afternoon on Nasdaq. (Editing by Anne

Pallivathuckal)

 

© Thomson

Reuters 2009. All rights reserved. Users may download and print

extracts of content from this website for their own personal and

non-commercial use only. Republication or redistribution of Thomson

Reuters contentincluding by framing or similar meansis expressly

prohibited without the prior written consent of Thomson Reuters.

Thomson Reuters and its logo are registered trademarks or trademarks of

the Thomson Reuters group of companies around the world.Thomson

Reuters journalists are subject to an Editorial Handbook which requires

fair presentation and disclosure of relevant interests.

 

http://nanocolors.wordpress.com/2009/08/07/nano-vaccines-volumetry-in-patents-since-2000/

 

Nano & vaccines : volumetry in patents since 2000Posted on August 72009 by nanocolors

 

This chart

was built by searching the Espacenet database for patents mentionning

the prefixes "nano" and "vaccin" in their title or abstract.

 

 

 

Filed under: Uncategorized | Tagged: HealthPatentsPharmaTrends